YiChang HEC ChangJiang Pharmaceutical Co Ltd 2022 SR
The report highlights Pharm HEC's 2022 performance, noting a 309.83% revenue increase driven by the recovery of its core anti-influenza product, Kewei. Key achievements include the launch of self-developed Insulin Aspart injections and the successful listing of Emtasvir Phosphate in the National Reimbursement Drug List. The company established a multi-level ESG governance structure and focused on green manufacturing, achieving a 100% compliance rate for pollutant emissions. Social initiatives included voluntary blood donations and anti-pandemic material donations.
Company: YiChang HEC ChangJiang Pharmaceutical Co Ltd
Sector: Health Care
Country: China
Year: 2022
Type: SR
Pages: 96
YiChang HEC ChangJiang Pharmaceutical Co Ltd
ESG Report
The report highlights Pharm HEC's 2022 performance, noting a 309.83% revenue increase driven by the recovery of its core anti-influenza product, Kewei. Key achievements include the launch of self-developed Insulin Aspart injections and the successful listing of Emtasvir Phosphate in the National Reimbursement Drug List. The company established a multi-level ESG governance structure and focused on green manufacturing, achieving a 100% compliance rate for pollutant emissions. Social initiatives included voluntary blood donations and anti-pandemic material donations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Mar 24, 2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees